Arcus Biosciences recently announced initial overall survival results from the Phase 2 EDGE-Gastric study, showing a median overall survival of 26.7 months for domvanalimab plus zimberelimab with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results